MV1

Moreover, TWEAK-MV1 greatly enhanced both apoptotic and necroptotic cell death both in vitro and in vivo, accompanied by cellular IAP degradation as well as activation of receptor-interacting protein kinase. Taken together, our preclinical data suggested that the designed conjugation compound of TWEAK and MV1 might provide a potential therapeutic strategy for cutaneous SCC with improved anti-tumor efficacy and negligible toxicity.